Key Development
AstraZeneca and Daiichi Sankyo are facing an increasingly complex risk-benefit equation for Enhertu (trastuzumab deruxtecan) in HER2-mutant non-small cell lung cancer. In the Phase III DESTINY-Lung04 trial, Enhertu reduced the risk of disease progression or death by 37% versus pembrolizumab plus platinum-pemetrexed chemotherapy. Median progression-free survival reached 14.3 months versus approximately 8.3 months, while objective response rate increased to 70% from 44.5%.
Yet the preliminary overall survival picture moved in the opposite direction. Median OS was 29.3 months with Enhertu versus 33.1 months with chemo-immunotherapy, translating into an approximately 15% higher interim risk of death in the Enhertu arm. The survival curves began favoring the control arm around 20 months after randomization. OS remains immature and had not been formally tested at this analysis, but the direction of the signal could materially complicate the regulatory case for moving Enhertu into first-line therapy.
Treatment sequencing may partially explain the discrepancy. Among patients receiving subsequent therapy, approximately 72% in the control arm later received a HER2-directed treatment, compared with only 39% in the Enhertu arm. This imbalance could improve long-term outcomes for patients initially receiving standard therapy, but it does not eliminate questions surrounding Enhertu’s first-line benefit-risk profile.
Why It Matters
- Superior PFS does not automatically translate into superior survival. In first-line oncology, the impact of subsequent treatments increasingly determines the true value of an initial therapy.
- ILD remains a strategic vulnerability. Drug-related ILD or pneumonitis was adjudicated in 20.8% of Enhertu-treated patients, while fatal ILD events reinforce the importance of early detection and aggressive toxicity management.
- The competitive landscape has moved quickly. The FDA expanded accelerated approvals for Boehringer Ingelheim’s Hernexeos (zongertinib) in February 2026 and Bayer’s Hyrnuo (sevabertinib) on September 9, 2026 into previously untreated HER2-mutant NSCLC.
- ADC leadership can no longer be taken for granted. Oral HER2 TKIs offer targeted alternatives that may reshape physician preferences and treatment sequencing.
Healthcare Insight Analysis
DESTINY-Lung04 highlights an increasingly important reality in oncology: strong tumor control alone may no longer be sufficient to secure the first-line position.
Enhertu has accomplished something clinically meaningful. It is the first HER2-directed therapy to demonstrate a PFS advantage over the existing global first-line standard in a randomized Phase III trial for HER2-mutant NSCLC, a molecular subgroup representing roughly 2%–4% of NSCLC.
But moving an ADC earlier also exposes patients earlier—and potentially for longer—to mechanism-associated toxicities such as ILD. As targeted therapies become increasingly effective across sequential lines, regulators and clinicians must evaluate not only what produces the deepest initial response, but which sequence maximizes survival across the patient’s entire treatment journey.
That distinction could determine Enhertu’s ultimate position. If chemo-immunotherapy followed by an effective HER2-directed agent generates comparable or better survival, the commercial question changes from whether Enhertu works to where Enhertu creates the greatest incremental value.
The implications extend beyond this individual program. As ADC developers push their assets from later-line disease into first-line and curative-intent settings, the competitive standard will increasingly move beyond ORR and PFS toward overall survival, cumulative toxicity and sequencing value.
Market Implications
For AstraZeneca and Daiichi Sankyo, DESTINY-Lung04 remains strategically important because randomized Phase III evidence gives Enhertu a level of comparative efficacy evidence that newer HER2 TKIs do not yet have in this setting.
However, the unfavorable interim survival trend gives regulators a reason for caution precisely as the market becomes more competitive. With two oral HER2 TKIs already carrying accelerated first-line U.S. approvals, Enhertu may face a higher commercial and regulatory threshold than it did when DESTINY-Lung04 was designed.
The HER2-mutant lung cancer market is therefore evolving from targeted therapy versus chemotherapy into a three-way contest between ADCs, oral TKIs and optimal treatment sequencing. The winners may ultimately be determined not by the highest response rate, but by the strongest balance of survival, CNS activity, safety and whole-of-treatment-pathway value.